NCT01715077View on ClinicalTrials.gov

Study of Ipilimumab in the Immune System

NACompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma
Interventions
DRUG

Ipilimumab at 3 mg/kg dose

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT01715077 - Study of Ipilimumab in the Immune System | Biotech Hunter | Biotech Hunter